Here's an article from Future Pundent in 2006:Cure For

New Post Public Reply Private Reply Replies (1) Message Board
L vus

Here's an article from Future Pundent in 2006: Cure For Cancer Worth $50 Trillion Just To Americans

The economic pay-off of medical research will be enormous when cures for cancer are developed. A couple of academic researchers claim that  a cure for cancer would have an economic value of $50 trillion for Americans alone . Add in the value of the cure to other industrialized societies that the total value of the cure likely exceeds $100 trillion.

A new study, to be published in a forthcoming issue of the Journal of Political Economy, calculates the prospective gains that could be obtained from further progress against major diseases. Kevin M. Murphy and Robert H. Topel, two University of Chicago researchers, estimate that even modest advancements against major diseases would have a significant impact – a 1 percent reduction in mortality from cancer has a value to Americans of nearly $500 billion. A cure for cancer would be worth about $50 trillion.

"We distinguish two types of health improvements – those that extend life and those that raise the quality of life," explain the authors. "As the population grows, as incomes grow, and as the baby-boom generation approaches the primary ages of disease-related death, the social value of improvements in health will continue to rise."

Many critiques of rising medical expenditures focus on life-extending procedures for persons near death. By breaking down net gains by age and gender, Murphy and Topel show that the value of increased longevity far exceeds rising medical expenditures overall. Gains in life expectancy over the last century were worth about $1.2 million per person to the current population, with the largest gains at birth and young age.

"An analysis of the value of health improvements is a first step toward evaluating the social returns to medical research and health-augmenting innovations," write the authors. "Improvements in life expectancy raise willingness to pay for further health improvements by increasing the value of remaining life."

Murphy and Topel also chart individual values resulting from the permanent reduction in mortality in several major diseases – including heart disease, cancer, and diabetes. Overall, reductions in mortality from 1970 to 2000 had an economic value to the U.S. population of $3.2 trillion per year.

In 2005 the US economy produced  $12.4 trillon worth of goods and services. So the value of a cancer cure equals over 4 years of US economic output.

The enormous economic value of curative treatments for cancer and similar magnitude economic value for cures for other major killers such as stroke and heart disease mean we can get huge the future returns on investment in public spending for basic biomedical research. This means increased biomedical research funding by governments is pretty easy to justify when viewed in economic terms. Yet in order to fund a war, pork, and other wastes  the Bush Administration has sought to cut biomedical research spending in inflation-adjusted terms and even  proposed a freeze in nominal dollar terms (which means that real research spending goes down by the rate at which inflation goes up).

The numbers bandied about above understate the coming return on decades of basic biomedical research. Rejuvenation therapies will lengthen working careers and brain rejuvenation will boost productivity for most years worked. Minds which have both youthful vigor and the knowledge and skills accumulated from decades of work will achieve much greater feats and operate at much higher levels of productivity.

Because the rate of advance of research can not be forecasted accurately I think there's a tendency on the part of policy makers and the public to underestimate the future return on biomedical research and in other forms of research as well. Our accumulating body of knowledge is going to reach a critical mass at some point in the next 50 years where the vast majority of diseases become curable and replacement or rejuvenation of worn aged body parts becomes commonplace. We ought try much harder to make that day come sooner.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Damp or Dry: The Battle for Healthy Air in Colorado

Updated Category News Views 4

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

Continue Reading
D-Wave Faces Legal Questions After CFO Exit and Losses

Updated Category News Views 1

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

Continue Reading
Pizza: The Unlikely Symbol of Universal Togetherness

Updated Category News Views 1

Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...

Continue Reading
SMPL Faces Legal Drama: What Investors Need to Know

Updated Category News Views 2

Investors Swim Against the Current With SMPL Picture this: You’re sipping your morning coffee, glancing through stocks, only to choke on your bagel when The Simply Good Foods Company (NASDAQ: SMPL) pops up with some less-than-palatable news. A class action is brewing, shouting out to investors who took the bait from October 24, 2024, to April 8, 2026. If you’re one of...

Continue Reading
Ajman Spotlights Tourism at Arabian Travel Market 2026

Updated Category News Views 2

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

Continue Reading
Delhi Pushes Innovation Against Dryland Challenges

Updated Category News Views 5

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

Continue Reading
Larry Ellison's Moves Signal Confidence in Oracle's Future

Updated Category News Views 5

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 8

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
Silk Road Maritime Extends Its Global Reach in 2026

Updated Category News Views 5

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...

Continue Reading
Protecting Teeth: Insights from Endodontist Dr. Joubert

Updated Category News Views 3

Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...

Continue Reading

Top 5 Most Recently Viewed Articles

Auriant Mining AB Reports Strong Q2 2024 Performance

Updated Category News Views 94

Auriant Mining AB Reports Strong Q2 2024 Performance Auriant Mining AB has released its interim report for the second quarter of 2024, highlighting a positive financial and operational performance for the first half of the year. Key Highlights In the first half of 2024, Auriant Mining achieved notable milestones in both gold production and sales. Gold Production: The...

Continue Reading
Orlance, Inc. Secures NIH Grant for Cutting-Edge Vaccine Development

Updated Category News Views 266

Orlance, Inc. Receives Significant Funding for Vaccine Development Orlance, Inc. has recently made headlines by securing a substantial $3.3 million grant from the National Institutes of Health (NIH) aimed at advancing its MACH-1™ enhanced seasonal influenza vaccine. This proactive step is geared towards improving vaccine effectiveness, especially in scenarios where...

Continue Reading
Analyzing Market Sentiment on BlackRock Inc's Short Interest

Updated Category News Views 171

Understanding BlackRock Inc's Stock Dynamics BlackRock Inc (NYSE: BLK) recently experienced a notable shift in its short interest, rising by 3.8% since the last report. Currently, there are approximately 1.24 million shares sold short, representing 0.82% of the available regular shares for trading. Based on the recent trading momentum, it would average around 2.33 days...

Continue Reading
Stora Enso Welcomes Jutta Mikkola as New IR Leader

Updated Category News Views 209

Stora Enso Appoints Jutta Mikkola to Lead Investor Relations Stora Enso has made significant strides by appointing Jutta Mikkola as the Senior Vice President and head of Investor Relations. In her new role at Stora Enso, Jutta will report directly to Niclas Rosenlew, the Chief Financial Officer. With a solid background in business and finance, Jutta’s expertise is...

Continue Reading
LiveOne Hosts Key Shareholders and Partners at Mar-a-Lago Event

Updated Category News Views 70

LiveOne’s Exclusive Shareholder Event at Mar-a-Lago In an exciting development for investors and stakeholders, LiveOne (NASDAQ: LVO), a renowned creator-first music and entertainment platform, is set to host a unique gathering at President Trump's Mar-a-Lago. This event, tailored for shareholders and prospective partners, aims to foster collaboration and showcase the...

Continue Reading